Traders bought shares of Pfizer (NYSE:PFE) on weakness during trading on Friday. $172.18 million flowed into the stock on the tick-up and $78.29 million flowed out of the stock on the tick-down, for a money net flow of $93.89 million into the stock. Of all equities tracked, Pfizer had the 21st highest net in-flow for the day. Pfizer traded down ($0.56) for the day and closed at $35.17
Several equities analysts recently weighed in on PFE shares. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Friday, December 8th. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research report on Wednesday, December 27th. Morgan Stanley set a $41.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a research report on Monday, January 8th. Finally, Jefferies Group set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and an average target price of $39.25.
The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. The company has a market cap of $215,077.02, a PE ratio of 13.27, a PEG ratio of 1.80 and a beta of 0.90.
Pfizer declared that its Board of Directors has initiated a stock repurchase plan on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.
In other news, EVP Sally Susman sold 33,368 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $37.03, for a total value of $1,235,617.04. Following the sale, the executive vice president now directly owns 191,505 shares in the company, valued at approximately $7,091,430.15. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares in the company, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders have sold 248,037 shares of company stock worth $9,064,785 over the last 90 days. Corporate insiders own 0.06% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in PFE. BlackRock Inc. boosted its holdings in shares of Pfizer by 2.8% in the 4th quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after acquiring an additional 12,183,218 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Pfizer by 11.9% in the 4th quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock worth $2,562,162,000 after acquiring an additional 7,534,957 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Pfizer by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company’s stock worth $2,281,563,000 after acquiring an additional 1,881,570 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Pfizer by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after acquiring an additional 2,502,659 shares in the last quarter. Institutional investors own 71.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Traders Buy Pfizer (PFE) on Weakness” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3336195/traders-buy-pfizer-pfe-on-weakness.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.